Autologous CD4-positive and CD8-positive T cells are genetically modified to express an anti-CD19 chimeric antigen receptor containing 4-1BB costimulatory and CD3-zeta signalling domains. After infusion, the cells recognise CD19-expressing B-lineage tumour cells and mediate T-cell activation, proliferation and cytotoxic killing.
Indications / reported uses
Treatment of adults with specified large B-cell lymphomas, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, in the treatment settings defined by the current product label.
The current US label includes selected earlier-line and later-line settings; primary central nervous system lymphoma is not an indicated use.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Lisocabtagene Maraleucel Environmental Risk Assessment (ERA) (the Lisocabtagene Maraleucel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.